Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis-Reference-Cited by-同舟云学术

Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis

Published:2022-06-21 Issue:6 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

van der Laan Louvina E.¹²^ORCID,Garcia-Prats Anthony J.²^ORCID,Schaaf H. Simon²,Chirehwa Maxwell¹^ORCID,Winckler Jana L.²,Mao Jun²,Draper Heather R.²,Wiesner Lubbe¹^ORCID,Norman Jennifer¹,McIlleron Helen¹^ORCID,Donald Peter R.²,Hesseling Anneke C.²,Denti Paolo¹^ORCID

Affiliation:

1. Desmond Tutu TB Center, Department of Pediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

2. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

Abstract

Treatment options for children with Rifampicin-resistant tuberculosis (RR-TB) remain limited, and para-aminosalicylic acid (PAS) is still a relevant component of treatment regimens. Prevention of resistance to companion drugs by PAS is dose related, and at higher concentrations, PAS may exhibit significant bactericidal activity in addition to its bacteriostatic properties.

Funder

HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development

South African National Research Foundation SArCHI

National Research Foundation

Wellcome Trust

HHS | NIH | National Institute of Allergy and Infectious Diseases

HHS | NIH | National Institute of Mental Health

Swedish Foundation for International Cooperation in Research and Higher Education

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02264-21

Reference63 articles.

1. WHO. 2021. WHO announces updated definitions of extensively drug-resistant tuberculosis. https://www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis. Accessed 9 March 2022.

2. Fluoroquinolone Resistance inMycobacterium tuberculosis

3. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study

4. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates

5. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis